Filtered By:
Vaccination: Ebola Vaccine
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 697 results found since Jan 2013.
News from Annals of Internal Medicine
(American College of Physicians) These articles are now available from the Annals of Internal Medicine: 'Opinion: The time to deploy Ebola vaccines is now'; and 'Opinion: Base US Ebola containment plans on evidence, not hysteria.'
Source: EurekAlert! - Medicine and Health - August 20, 2014 Category: Global & Universal Source Type: news
Ebola: Is It Fair That Americans Received the Treatment?Ebola: Is It Fair That Americans Received the Treatment?
Many are worried about a potential spread of Ebola, but another challenge is determining who would get treatment or vaccines that might prevent transmission down the road. Medscape Business of Medicine
Source: Medscape Business of Medicine Headlines - August 21, 2014 Category: Pharmaceuticals Tags: Family Medicine/Primary Care Commentary Source Type: news
What 1989 And The Golden Girls Tell Us About Medicine Today
Today, 1989 may be most associated with Taylor Swift: It is the album that won her a second Grammy for Album of the Year. Not only that, it happens to be the year Swift was born--such a long, long time ago!
People under 35 have no personal memory of 1980s pop culture, which is ironic since Swift's album in part pays homage to it. In the real 1989 (no offense to Swift and the 10 co-producers who made the album), all sorts of revolutions took place: Mr. Gorbachev tore down that pesky wall, for example. America's greatest antagonist, the Soviet Union, collapsed in 1989. Brazil conducted its first democratic presidential ...
Source: Healthy Living - The Huffington Post - September 23, 2016 Category: Consumer Health News Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
University of Maryland School of Medicine begins Ebola vaccine trails in Mali
(University of Maryland School of Medicine) Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and University of Maryland School of Medicine Dean E. Albert Reece MD, PhD, MBA, announced today that the Center for Vaccine Development, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers and other front-line workers to evaluate a promising experimental Ebola vaccine.
Source: EurekAlert! - Infectious and Emerging Diseases - October 9, 2014 Category: Infectious Diseases Source Type: news
University of Maryland School of Medicine begins Ebola vaccine trials in Mali
(University of Maryland School of Medicine) Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and University of Maryland School of Medicine Dean E. Albert Reece MD, PhD, MBA, announced today that the Center for Vaccine Development, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers and other front-line workers to evaluate a promising experimental Ebola vaccine.
Source: EurekAlert! - Infectious and Emerging Diseases - October 9, 2014 Category: Infectious Diseases Source Type: news
Current views and advances on Paediatric Virology: An update for paediatric trainees.
Authors: Mammas IN, Greenough A, Theodoridou M, Kramvis A, Christaki I, Koutsaftiki C, Koutsaki M, Portaliou DM, Kostagianni G, Panagopoulou P, Sourvinos G, Spandidos DA
Abstract
Paediatric Virology is a bold new scientific field, which combines Paediatrics with Virology, Epidemiology, Molecular Medicine, Evidence-based Medicine, Clinical Governance, Quality Improvement, Pharmacology and Immunology. The Workshop on Paediatric Virology, which took place on Saturday October 10, 2015 in Athens, Greece, provided an overview of recent views and advances on viral infections occurring in neonates and children. It was incl...
Source: Experimental and Therapeutic Medicine - February 20, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
Ebola Virus Outbreak 2014: Clinical Review for Emergency Physicians
This article seeks to provide emergency physicians with the essential and up-to-date information required to identify, evaluate, and manage Ebola viral disease and to join global efforts to contain the current outbreak.
Source: Annals of Emergency Medicine - October 31, 2014 Category: Emergency Medicine Source Type: research
Perspectives on Ebola.
Abstract
An unprecedented epidemic of Ebola virus disease (EVD) unfolded in West Africa in 2014. The epidemic has been well described in the popular press and in regular reports from public health authorities. The medical literature has necessarily been slower in describing the epidemic, but comprehensive reports are now appearing, offering valuable accounts of the clinical features, epidemiology, and public health consequences of this terrifying disease. The American Society of Tropical Medicine and Hygiene (ASTMH) has been deeply involved with the EVD outbreak. Numerous ASTMH members have played major roles in a...
Source: The American Journal of Tropical Medicine and Hygiene - January 12, 2015 Category: Tropical Medicine Authors: Rosenthal PJ, Bausch DG Tags: Am J Trop Med Hyg Source Type: research
Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from this Phase ...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Ebola Vaccine — An Urgent International Priority
New England Journal of Medicine, Volume 0, Issue 0, Ahead of Print.
Source: New England Journal of Medicine - October 7, 2014 Category: Internal Medicine Tags: article Source Type: research
The Price of Staying Alive For the Next 3 Hours
How much do you reckon you’d pay not to be dead three hours from now? That probably depends. If you’re 25 and healthy, a whole lot. If you’re 95 and sickly, maybe not so much. But for people in one part of the world—the former East Germany—the cost has been figured out, and it’s surprisingly cheap: three hours of life will set you back (or your government, really) just one euro, or a little below a buck-thirty at current exchange rates.
That’s the conclusion of a new study out of Germany’s Max Planck Institute, and it says a lot about the power of a little bit of money now to...
Source: TIME: Top Science and Health Stories - October 15, 2014 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized ebola epidemiology Health Care health insurance Life Expectancy medicine polio prevention syringes Source Type: news
Africa: Nigeria to Begin Ebola Vaccine Trial
[Guardian]Abuja -THE Supervising Minister of Health, Dr. Khaliru Alhassan, Monday disclosed that Nigeria is set to follow internationally-approved protocols to commence clinical trial of Ebola vaccines developed by its researchers and some of the candidate vaccines currently in the global medicine community.
Source: AllAfrica News: Health and Medicine - November 11, 2014 Category: African Health Source Type: news
One Step Closer to an Ebola Virus Vaccine
New England Journal of Medicine, Volume 0, Issue 0, Ahead of Print.
Source: New England Journal of Medicine - November 26, 2014 Category: Internal Medicine Tags: article Source Type: research
